Fangxu Wang
Biographic Data
| ID | 10007079 |
|---|---|
| NAME | Fangxu Wang |
| GIVEN NAMES | Fangxu |
| FAMILY NAME | Wang |
| SIGNATURE | WANG F |
| AFFILIATIONS | Peking University |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 1 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Cost-utility analysis of telitacicept versus belimumab in the treatment of systemic lupus erythematosus in China
Objective: Telitacicept and belimumab are the only two approved biologics in China for treating systemic lupus erythematosus (SLE). With the widespread clinical use of biologics, more reliable clinical evidence has been provided. This study seeks to evaluate the cost-effectiveness of two biologic treatments for SLE in China by utilizing current medication prices and the most recent clinical research. Methods: A cost-effectiveness analysis compari…
No prominent works on this page.
Cost-utility analysis of telitacicept versus belimumab in the treatment of systemic lupus erythematosus in China
Objective: Telitacicept and belimumab are the only two approved biologics in China for treating systemic lupus erythematosus (SLE). With the widespread clinical use of biologics, more reliable clinical evidence has been provided. This study seeks to evaluate the cost-effectiveness of two biologic treatments for SLE in China by utilizing current medication prices and the most recent clinical research. Methods: A cost-effectiveness analysis compari…
Belimumab (1 works) · China (1 works) · Disease management (1 works) · Lupus erythematosus (1 works) · Medication adherence (1 works) · MEDLINE (1 works) · Monoclonal and Polyclonal Antibodies Research (1 works) · Rheumatoid Arthritis Research and Therapies (1 works) · Systemic Lupus Erythematosus Research (1 works)